Serafim  Papadimitriou

Mohamad Hussein

Professor

biography

Mohamad Hussein, MD, is VP Global Multiple Myeloma Franchise at Celgene Corporation Professor of Medicine and Oncology at the University of South Florida, Tampa, FL Dr. Hussein practiced at the Cleveland clinic Foundation, Cleveland, OH for two decades. During his tenure,developed and Directed the multiple myeloma research program at the Cleveland clinic 1996-2006.In January 2006 assumed a position as Professor of Oncology and Medicine, Clinical Director, Malignant Hematology Division, Director of the Myeloma section and Leader, Myeloma Clinical Research at the H Lee Moffitt Cancer Center, and the Univ of South Florida, Tampa FL 2006-2008 and currently Professor of Medicine and Oncology at the University of South Florida, Tampa FL. In August 2008, Dr. Hussein, Joined Celgene Corporation as the VP of Hematology Global Medical Affairs, May 2010 was appointed VP of Americas Medical Affairs,October 2012 VP of Global Scientific Affairs and September 2014 Global Multiple Myeloma Franchise .Dr. Hussein, who is board-certified in medical oncology and internal medicine. He has chaired and conducted over 20 clinical trials resulting in more than 150 published peer-review manuscripts, book chapters, and editorials to his credit. Dr Hussein serves on several committees that includedthe ASCO CME.

 

Area of Interest

1)Initiated immunology
2)Immune Therapy
3)Hematology
4)Oncology
5)Cancer Research
6)Leukemia research
7)Bone marrow Transplant.


top publication

1. Zonder JA, Crowley J, Hussein MA, Bolejack V, Moore DF, Sr., Whittenberger BF, Abidi MH, Durie BG, Barlogie B: Lenalidomide and high-dose dexamethasone compared with dexamethasone as initial therapy for multiple myeloma: a randomized Southwest Oncology Group trial (S0232). Blood 2010;116:5838-5841.

2. Baz R, Patel M, Finley-Oliver E, Lebovic D, Hussein MA, Miller KC, Wood M, Sher T, Lee K, Chanan-Khan AA: Single agent lenalidomide in newly diagnosed multiple myeloma: a retrospective analysis. Leuk Lymphoma 2010;51:1015-1019.

3. Khoriaty R, Hussein MA, Faiman B, Kelly M, Kalaycio M, Baz R: Prediction of response and progression in multiple myeloma with serum free light chains assay: corroboration of the serum free light chain response definitions. Clin Lymphoma Myeloma Leuk 2010;10:E10-E13.

4. Hartley MA, Sokol L, Caceres G, Hussein MA, List A, Pinilla-Ibarz J: Monoclonal gammopathy of undetermined significance disguised as chronic neutrophilic leukemia. Mediterr J Hematol Infect Dis 2010;2:e2010002

. 5. Dimopoulos MA, Hussein M, Swern AS, Weber D: Impact of lenalidomide dose on progression-free survival in patients with relapsed or refractory multiple myeloma. Leukemia 2011.Khoriaty R, Hussein MA, Faiman B, Kelly M, Kalaycio M, Baz R: Prediction of response and progression in multiple myeloma with serum free light chains assay: corroboration of the serum free light chain response definitions. Clin Lymphoma Myeloma Leuk 2010, 10(1):E10-13.

6. Hussein M, Berenson JR, Niesvizky R, Munshi N, Matous J, Sobecks R, Harrop K, Drachman JG, Whiting N: A phase I multidose study of dacetuzumab (SGN-40; humanized anti-CD40 monoclonal antibody) in patients with multiple myeloma. Haematologica 2010, 95(5):845-848.

7. Baz R, Patel M, Finley-Oliver E, Lebovic D, Hussein MA, Miller KC, Wood M, Sher T, Lee K, Chanan-Khan AA: Single agent lenalidomide in newly diagnosed multiple myeloma: a retrospective analysis. Leuk Lymphoma 2010, 51(6):1015-1019.

8. Srkalovic G, Hussein M: Immunomodulatory compounds (IMiDs) in the treatment of multiple myeloma. Bosn J Basic Med Sci 2009, 9 Suppl 1:3-10.

9. Siegel D, Hussein M, Belani C, Robert F, Galanis E, Richon VM, Garcia-Vargas J, Sanz-Rodriguez C, Rizvi S: Vorinostat in solid and hematologic malignancies. J Hematol Oncol 2009, 2:31.

10. Richardson PG, San-Miguel J, Lonial S, Reece D, Jakubowiak A, Hussein M, Jagannath S, Mitsiades CS, Raje N, Kaufman J et al: The research mission in myeloma. Leukemia 2009, 23(2):422-423; author reply 423-424.

11. Richardson P, Jagannath S, Hussein M, Berenson J, Singhal S, Irwin D, Williams SF, Bensinger W, Badros AZ, Vescio R et al: Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma. Blood 2009, 114(4):772-778.

12. Palumbo A, Dimopoulos M, San Miguel J, Harousseau JL, Attal M, Hussein M, Knop S, Ludwig H, von Lilienfeld-Toal M, Sonneveld P: Lenalidomide in combination with dexamethasone for the treatment of relapsed or refractory multiple myeloma. Blood Rev 2009, 23(2):87-93.

13. Kelley TW, Baz R, Hussein M, Karafa M, Cook JR: Clinical significance of cyclin D1, fibroblast growth factor receptor 3, and p53 immunohistochemistry in plasma cell myeloma treated with a thalidomide-based regimen. Hum Pathol 2009, 40(3):405-412.

14. Hussein MA, Bolejack V, Zonder JA, Durie BG, Jakubowiak AJ, Crowley JJ, Barlogie B: Phase II study of thalidomide plus dexamethasone induction followed by tandem melphalan-based autotransplantation and thalidomide-plus-prednisone maintenance for untreated multiple myeloma: a southwest oncology group trial (S0204). J Clin Oncol 2009;27:3510-3517.

15. Palumbo A, Dimopoulos M, San MJ, Harousseau JL, Attal M, Hussein M, Knop S, Ludwig H, von Lilienfeld-Toal M, Sonneveld P: Lenalidomide in combination with dexamethasone for the treatment of relapsed or refractory multiple myeloma. Blood Rev 2009;23:87-93.

16. Richardson P, Jagannath S, Hussein M, Berenson J, Singhal S, Irwin D, Williams SF, Bensinger W, Badros AZ, Vescio R, Kenvin L, Yu Z, Olesnyckyj M, Zeldis J, Knight R, Anderson KC: Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma. Blood 2009;114:772-778.

17. Richardson PG, San-Miguel J, Lonial S, Reece D, Jakubowiak A, Hussein M, Jagannath S, Mitsiades CS, Raje N, Kaufman J, Avigan D, Ghobrial I, Schlossman RL, Munshi N, Dalton W, Anderson KC: The research mission in myeloma. Leukemia 2009;23:422-423.

18. Siegel D, Hussein M, Belani C, Robert F, Galanis E, Richon VM, Garcia-Vargas J, Sanz-Rodriguez C, Rizvi S: Vorinostat in solid and hematologic malignancies. J Hematol Oncol 2009;2:31.

19. Hsi ED, Steinle R, Balasa B, Szmania S, Draksharapu A, Shum BP, Huseni M, Powers D, Nanisetti A, Zhang Y, Rice AG, van AA, Wong M, Liu G, Zhan F, Dillon M, Chen S, Rhodes S, Fuh F, Tsurushita N, Kumar S, Vexler V, Shaughnessy JD, Jr., Barlogie B, van RF, Hussein M, Afar DE, Williams MB: CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma. Clin Cancer Res 2008;14:2775-2784.

20. Koomen JM, Haura EB, Bepler G, Sutphen R, Remily-Wood ER, Benson K, Hussein M, Hazlehurst LA, Yeatman TJ, Hildreth LT, Sellers TA, Jacobsen PB, Fenstermacher DA, Dalton WS: Proteomic contributions to personalized cancer care. Mol Cell Proteomics 2008;7:1780-1794

Book Chapters
1. Baz R, Hussein MA. Multiple Myeloma, Other plasma cell dyscrasias and Primary Amyloidosis; Handbook of Cancer Chemotherapy, Roland Skeel, 20xx, 8th Edition, in press. 2. Hussein MA. Surgical Management of Bone Disease; Myeloma Bone Disease, G David Roodman, 2010, 1st Edition, Chapter 5, 101-116
3. Baz R, Hussein MA. Multiple Myeloma, Other plasma cell dyscrasias and Primary Amyloidosis; Handbook of Cancer Chemotherapy, Roland Skeel, 2007, 7th Edition, Chapter 24, 572-592.
4. Rachid Baz, Hussein MA, Uncommon Presentations of Plasma Cell Dyscrasias Textbook of Uncommon Cancer 2006, Third Edition Pages: 569–575
5. Fanning SR, Hussein MA. Monoclonal Gammopathy of Undetermined Significance. e-medicine, Medical Oncology, Online 2006
6. Fanning SR, Hussein MA. Light Chain Disease. e-medicine, Medical Oncology, Online 2006.
7. Hussein, MA, Multiple Myeloma and Plasmacytoma: Cancer in the Spine, Comprehensive Care, Editor: Robert F. McLain 101-106, 2005
8. Hussein MA, Oken M. Plasma Cell Dyscrasia Diagnosis And Management. Clinical Practice Of Hematology & Oncology , 2005
9. Borden EC, Lindner D, Dreicer R, Hussein MA, Peereboom D. The Role of Interferon in Multiple Myeloma. Second Generation Interferons for Cancer: Clinical Targets. Semin Cancer Biol 2000 Apr;10(2): 125-144
10. Perez-Zincer F, Hussein M. Plasmacytoma. e-medicine (www.emedicine.com) Editor: Rodger L. Bick, M.D., Ph.D., 2001.
11. Juturi J, Hussein MA. Monoclonal Gammopathy of Undetermined Significance. e-medicine, Medical Oncology, 2002
12. Juturi J, Hussein MA. Light Chain Disease. e-medicine, Medical Oncology, 2003.
13. Hussein MA. Multiple Myeloma, in Hurst JW (4th ed.): Medicine for the Practicing Physician. Stamford, CT: Appleton and Lange, 1996. Chapter 12-28, pp.884-887.